During the corresponding time, Pacira Biosciences Inc recorded a revenue increase by 6.24 % year on year, sequentially revenue grew by 8.47 %. While revenue at the Pacira Biosciences Inc 's corporate clients
Pacira Biosciences Inc's Comment on Sales, Marketing and Customers
The company serves healthcare practitioners involved in pain management decisions, including anesthesiologists, surgeons, pharmacists, and physician extenders such as physician assistants, nurse practitioners, and registered nurses. It collaborates with hospital staff, including heads of quality and executives, to provide resources for drug utilization and health outcomes studies. The company engages key opinion leaders and advisory boards to develop best practice guidelines and protocols. Its educational initiatives target physicians, surgeons, anesthesiologists, pharmacists, and registered nurses through programs such as centers of excellence, preceptorships, opioid-sparing protocols, and patient education platforms. The company works with healthcare providers to enhance pain management knowledge, focusing on opioid risk and non-opioid alternatives, and supports reimbursement efforts and transitions to outpatient and ambulatory surgery center sites of care.
Osteoarthritis (OA) is a progressive degenerative disease characterized by the breakdown of cartilage and underlying bone, leading to significant pain and functional limitations. The potential for gene therapy to offer a durable solution for managing OA symptoms has garnered considerable attention. This review presents findings from the recent unveiling of three-year clinical data for the investigational gene therapy, PCRX-201, developed by Pacira BioSciences. These data demonstrate that a single local administration of PCRX-201 in patients with moderate-to-severe knee OA resulted in sustained improvements in pain management, reduction in stiffness, and enhancement of functional capabilities lasting up to t...
: Pacira BioSciences, an industry leader in non-opioid pain management, has made a significant advancement in its billing and reimbursement processes for EXPAREL, a bupivacaine liposome injectable suspension. Following the announcement of a new Healthcare Common Procedure Coding System (HCPCS) J-code, J0666, set to take effect on January 1, 2025, Pacira is poised for enhanced operational efficiency, improved provider accessibility, and increased patient utilization of its innovative pain management product.Non-opioid pain management represents a transformative approach to alleviating pain while mitigating the risk of addiction associated with opioid medications. Pacira BioSciences has established itself as a...
Pacira Biosciences Inc’s Comment on Sales, Marketing and Customers
The company serves healthcare practitioners involved in pain management decisions, including anesthesiologists, surgeons, pharmacists, and physician extenders such as physician assistants, nurse practitioners, and registered nurses. It collaborates with hospital staff, including heads of quality and executives, to provide resources for drug utilization and health outcomes studies. The company engages key opinion leaders and advisory boards to develop best practice guidelines and protocols. Its educational initiatives target physicians, surgeons, anesthesiologists, pharmacists, and registered nurses through programs such as centers of excellence, preceptorships, opioid-sparing protocols, and patient education platforms. The company works with healthcare providers to enhance pain management knowledge, focusing on opioid risk and non-opioid alternatives, and supports reimbursement efforts and transitions to outpatient and ambulatory surgery center sites of care.
Sources:
Pacira Biosciences inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Pacira Biosciences inc’s corporate clients.
For your research, we’ve provided 9 tables on Pacira Biosciences inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
191.2 %